Stocktoria
Cyclerion Therapeutics, Inc. CYCN
Cyclerion Therapeutics, Inc. (CYCN) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $2.1M at a -170.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CYCN | Cyclerion Therapeutics, Inc. | 1/9 | — | — | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 1/9 | 14.17 | — | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | 2/9 | 7.8 | 3 | — |
| LPCN | Lipocine Inc. | — | — | — | -82.3% |
| BIOE | Bio Essence Corp | 9/9 | — | 14.1 | — |
| CLSDQ | Clearside Biomedical, Inc. | 2/9 | — | — | — |
| GOVX | GeoVax Labs, Inc. | 1/9 | — | — | — |
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
FAQ
Is CYCN financially healthy?
Cyclerion Therapeutics, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does CYCN pay a dividend?
No, Cyclerion Therapeutics, Inc. does not currently pay a dividend.
How profitable is CYCN?
In FY2025, Cyclerion Therapeutics, Inc. had a net margin of -170.1% and a return on equity of -38.8%.
What is the analyst price target for CYCN?
The average Wall-Street price target for Cyclerion Therapeutics, Inc. is $8.00, about 104.1% above the recent price, from 1 analysts.
Is CYCN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Cyclerion Therapeutics, Inc.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.